Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. 1992

K Yalaz, and B Anlar, and F Oktem, and S Aysun, and S Ustacelebi, and O Gurcay, and K Gucuyener, and Y Renda
Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey.

We treated 22 patients with subacute sclerosing panencephalitis (SSPE) with intraventricular alpha-interferon (IFN) and inosiplex PO and followed them for 2 to 54 months. Three deaths occurred. Clinical improvement, demonstrated by decreasing scores on the Neurological Disability Index, occurred in 11/22 (50%); five patients became stable, and the progression rate of the disease decreased in three. The remission rate was significantly higher than untreated controls from the same institution. Patients who had a slowly progressive disease responded best to treatment. Serious side effects were rare. We recommend intraventricular IFN, combined with oral inosiplex, in the treatment of SSPE.

UI MeSH Term Description Entries
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D007542 Inosine Pranobex An alkylamino-alcohol complex of inosine used in the treatment of a variety of viral infections. Unlike other antiviral agents, it acts by modifying or stimulating cell-mediated immune processes rather than acting on the virus directly. Inosiplex,Methisoprinol,Imunovir,Isoprinosin,Isoprinosine,Methysoprinol,Metisoprinol,NPT-10381,NPT 10381,NPT10381,Pranobex, Inosine
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013344 Subacute Sclerosing Panencephalitis A rare, slowly progressive encephalitis caused by chronic infection with the MEASLES VIRUS. The condition occurs primarily in children and young adults, approximately 2-8 years after the initial infection. A gradual decline in intellectual abilities and behavioral alterations are followed by progressive MYOCLONUS; MUSCLE SPASTICITY; SEIZURES; DEMENTIA; autonomic dysfunction; and ATAXIA. DEATH usually occurs 1-3 years after disease onset. Pathologic features include perivascular cuffing, eosinophilic cytoplasmic inclusions, neurophagia, and fibrous gliosis. It is caused by the SSPE virus, which is a defective variant of MEASLES VIRUS. (From Adams et al., Principles of Neurology, 6th ed, pp767-8) Encephalitis, Inclusion Body, Measles,Leukoencephalitis, Subacute Sclerosing,Measles Inclusion Body Encephalitis,Panencephalitis, Subacute Sclerosing,SSPE,Van Bogaert's Leukoencephalitis,Inclusion Body Encephalitis, Measles,Leukoencephalitis, Van Bogaert's,Sclerosing Leukoencephalitis, Subacute,Sclerosing Panencephalitis, Subacute,Leukoencephalitides, Subacute Sclerosing,Leukoencephalitis, Van Bogaert,Leukoencephalitis, Van Bogaerts,Panencephalitides, Subacute Sclerosing,Sclerosing Leukoencephalitides, Subacute,Sclerosing Panencephalitides, Subacute,Subacute Sclerosing Leukoencephalitides,Subacute Sclerosing Leukoencephalitis,Subacute Sclerosing Panencephalitides,Van Bogaert Leukoencephalitis,Van Bogaerts Leukoencephalitis

Related Publications

K Yalaz, and B Anlar, and F Oktem, and S Aysun, and S Ustacelebi, and O Gurcay, and K Gucuyener, and Y Renda
January 1989, Journal of child neurology,
K Yalaz, and B Anlar, and F Oktem, and S Aysun, and S Ustacelebi, and O Gurcay, and K Gucuyener, and Y Renda
August 1991, Annals of neurology,
K Yalaz, and B Anlar, and F Oktem, and S Aysun, and S Ustacelebi, and O Gurcay, and K Gucuyener, and Y Renda
December 2003, Journal of child neurology,
K Yalaz, and B Anlar, and F Oktem, and S Aysun, and S Ustacelebi, and O Gurcay, and K Gucuyener, and Y Renda
September 2002, Journal of child neurology,
K Yalaz, and B Anlar, and F Oktem, and S Aysun, and S Ustacelebi, and O Gurcay, and K Gucuyener, and Y Renda
June 1979, Archives of neurology,
K Yalaz, and B Anlar, and F Oktem, and S Aysun, and S Ustacelebi, and O Gurcay, and K Gucuyener, and Y Renda
January 1998, Neurology,
K Yalaz, and B Anlar, and F Oktem, and S Aysun, and S Ustacelebi, and O Gurcay, and K Gucuyener, and Y Renda
April 1986, Neurology,
K Yalaz, and B Anlar, and F Oktem, and S Aysun, and S Ustacelebi, and O Gurcay, and K Gucuyener, and Y Renda
August 2003, The Kaohsiung journal of medical sciences,
K Yalaz, and B Anlar, and F Oktem, and S Aysun, and S Ustacelebi, and O Gurcay, and K Gucuyener, and Y Renda
January 1993, Brain & development,
K Yalaz, and B Anlar, and F Oktem, and S Aysun, and S Ustacelebi, and O Gurcay, and K Gucuyener, and Y Renda
January 1989, Brain & development,
Copied contents to your clipboard!